LONDON (ShareCast) - (Sharecast News) - Crystal Amber said on Wednesday that its portfolio company Morphic Medical has secured commercial registration from the UK Medicines and Healthcare products Regulatory Agency for its 'RESET' endoscopic treatment for obesity and type 2 diabetes, paving the way for UK sales.
The AIM-traded firm said the milestone followed CE mark certification in July, enabling RESET to be sold across Europe and in other countries recognising EU standards.

Morphic Medical had already started offering the treatment in Germany, with plans to expand further across the region.

It said clinical studies showed RESET patients lost an average of 19% of their body weight within a year, exceeding international safety and efficacy benchmarks for endoscopic weight-loss procedures.

The 20-minute outpatient treatment reportedly provides lasting weight and blood sugar control benefits without major surgery or reliance on drug therapies such as GLP-1 agonists.

"We're delighted to achieve MHRA registration, which marks an important step in the journey to commercialising the RESET therapy in the UK and help hundreds of thousands of people improve their health, while offering governments a cost-effective alternative to drug-based treatments," said chief executive Mike Gutteridge.

"Coming so soon after our CE mark certification, the momentum behind the business is building quickly and we remain hugely excited by the scale of the opportunity."

At 0922 BST, shares in Crystal Amber were down 1.38% at 152.86p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE